This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Applied Therapeutics 将来の成長

Future 基準チェック /26

Applied Therapeuticsの収益は年間33.9%で減少すると予測されていますが、年間収益は年間55.3%で増加すると予想されています。EPS は年間0.05%で減少すると予想されています。

主要情報

-33.9%

収益成長率

-0.049%

EPS成長率

Biotechs 収益成長	25.4%
収益成長率	55.3%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	12 Dec 2025

今後の成長に関する最新情報

Recent updates

分析記事 • Jul 15

Here's Why Applied Therapeutics (NASDAQ:APLT) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

分析記事 • Nov 15

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Applied...

Seeking Alpha • Sep 18

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Summary FDA removes the need for an advisory panel to first give a recommendation review of Applied Therapeutics, Inc.'s govorestat for the treatment of patients with galactosemia. PDUFA date of November 28th, 2024, remains on track for the FDA to decide whether govorestat should be approved to treat patients with galactosemia. Pre-NDA meeting with FDA expected in 2nd half of 2024 to discuss possible administrative actions of NDA filing submission of govorestat for the treatment of patients with SORD deficiency. If the pre-NDA meeting of govorestat for SORD deficiency goes well, then the company would be in a good position to file an NDA for this drug in Q1 of 2025. Read the full article on Seeking Alpha

Seeking Alpha • Sep 04

Applied Therapeutics: Pushing Towards FDA Approval

Summary Today, we revisit clinical stage developmental concern Applied Therapeutics, Inc. for the first time in 2024. The company is moving towards its first FDA approval before yearend, and could garner another approval for a different indication in 2025. An updated analysis around Applied Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha

分析記事 • Aug 01

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Applied...

Seeking Alpha • May 28

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

Summary Applied Therapeutics develops govorestat for rare diseases and AT-001 for diabetic cardiomyopathy; both are aldose reductase inhibitors. Govorestat shows promise as a treatment for galactosemia by preventing galactose conversion. AT-001’s efficacy in diabetic cardiomyopathy is inconclusive; significant results are only in certain subgroups. Hold APLT stock due to high risks despite potential in niche markets; it's suitable for a diversified high-risk portfolio segment. Read the full article on Seeking Alpha

Seeking Alpha • Feb 16

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Summary Positive 12-month interim results from the phase 3 INSPIRE study using govorestat for the treatment of patients with SORD deficiency achieved. Pre-NDA meeting with FDA to be sought out after to see if an NDA submission of govorestat for SORD deficiency could be done with only the positive 12-month interim data. 24-month interim results from the phase 3 INSPIRE study, using govorestat for the treatment of patients with SORD deficiency, is the next data readout to be expected. The NDA of govorestat for galactosemia has been submitted by the FDA and the EMA has validated the MAA; There is a good chance that Applied Therapeutics could receive regulatory approval for one or both of these territories. Read the full article on Seeking Alpha

分析記事 • Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. Indeed, Applied Therapeutics...

分析記事 • Nov 13

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Applied Therapeutics shares were hammered this month after FDA did not agree to accelerated approval for its drug candidate AT-007 in treating galactosemia in children. Investors and sell-side analysts are completely discounting the potential of the pipeline. Even in a conservative scenario, shares could reach $165 by 2028 or 38x upside potential. I provide various scenarios and my calculations on revenue potential, and enterprise value potential.

分析記事 • Nov 11

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

分析記事 • Aug 13

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

分析記事 • May 15

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

分析記事 • Feb 26

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Investors who take an interest in Applied Therapeutics, Inc. ( NASDAQ:APLT ) should definitely note that the...

業績と収益の成長予測

NasdaqCM:APLT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	65	N/A	N/A	N/A	1
12/31/2027	4	-83	N/A	N/A	2
12/31/2026	1	-69	N/A	N/A	4
12/31/2025	1	-76	N/A	N/A	4
9/30/2025	1	-18	-87	-87	N/A
6/30/2025	0	-68	-92	-92	N/A
3/31/2025	0	-44	-94	-94	N/A
12/31/2024	0	-106	-84	-84	N/A
9/30/2024	0	-187	-82	-82	N/A
6/30/2024	0	-161	-73	-73	N/A
3/31/2024	0	-194	-67	-67	N/A
12/31/2023	10	-120	-55	-55	N/A
9/30/2023	11	-97	-54	-54	N/A
6/30/2023	11	-73	-59	-59	N/A
3/31/2023	11	-70	-61	-61	N/A
12/31/2022	N/A	-83	-78	-78	N/A
9/30/2022	N/A	-95	-89	-89	N/A
6/30/2022	N/A	-105	-85	-85	N/A
3/31/2022	N/A	-105	-93	-93	N/A
12/31/2021	N/A	-106	-91	-91	N/A
9/30/2021	N/A	-102	-87	-87	N/A
6/30/2021	N/A	-104	-92	-92	N/A
3/31/2021	N/A	-106	-82	-82	N/A
12/31/2020	N/A	-94	-78	-78	N/A
9/30/2020	N/A	-88	-68	-68	N/A
6/30/2020	N/A	-69	-55	-55	N/A
3/31/2020	N/A	-49	-48	-48	N/A
12/31/2019	N/A	-46	-36	-36	N/A
9/30/2019	N/A	-35	-30	-30	N/A
6/30/2019	N/A	-28	N/A	-24	N/A
3/31/2019	N/A	-23	N/A	-17	N/A
12/31/2018	N/A	-17	N/A	-11	N/A

アナリストによる今後の成長予測

収入対貯蓄率: APLT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: APLT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: APLT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: APLTの収益 ( 55.3% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: APLTの収益 ( 55.3% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: APLTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/02/02 20:20
終値	2026/02/02 00:00
収益	2025/09/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Applied Therapeutics, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。7

アナリスト	機関
Carter Gould	Barclays
Paul Choi	Goldman Sachs
Luke Davis	RBC Capital Markets

This company has been acquired

Applied Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates decrease by 73%, EPS upgraded

Price target decreased by 50% to US$3.17

Consensus revenue estimates decrease by 38%

Consensus revenue estimates decrease by 26%

Forecast to breakeven in 2026

Consensus EPS estimates fall by 36%

Recent updates

Cycle Group Holdings Limited completed the acquisition of Applied Therapeutics, Inc. (NasdaqCM:APLT) for approximately $14.3 million.

Wolf Popper LLP Announces A Proposed Class Action Settlement Regarding Purchasers of Applied Therapeutics, Inc. Common Stock

Cycle Group Holdings Limited entered into a definitive agreement to acquire Applied Therapeutics, Inc. (NasdaqCM:APLT) for $13.4 million.

Applied Therapeutics Announces Reduction of Workforce by Approximately 46%

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Applied Therapeutics, Inc. Announces Resignation of John Johnson as Executive Chairman and as Director in November 2025

Applied Therapeutics, Inc. Provides Update Following Meeting with FDA

New major risk - Share price stability

Applied Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Consensus revenue estimates decrease by 73%, EPS upgraded

Price target decreased by 50% to US$3.17

First half 2025 earnings released: US$0.30 loss per share (vs US$0.60 loss in 1H 2024)

Here's Why Applied Therapeutics (NASDAQ:APLT) Must Use Its Cash Wisely

Applied Therapeutics Announces Leadership Appointments

Applied Therapeutics, Inc. Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

Applied Therapeutics, Inc., Annual General Meeting, Jun 09, 2025

Applied Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Applied Therapeutics, Inc. announced delayed annual 10-K filing

Applied Therapeutics, Inc. Appoints Todd F. Baumgartner as Chief Regulatory Officer

Applied Therapeutics Receives Written Notification from Nasdaq Regarding Bid Price Requirement

Applied Therapeutics, Inc. Appoints Reena Thomas Colacot as Head of Quality

Applied Therapeutics, Inc Announces Chief Executive Officer Changes

Robbins Geller Rudman & Dowd LLP Announces That Applied Therapeutics, Inc. Investors with Substantial Losses Has Opportunity to Lead the Applied Therapeutics Class Action Lawsuit

Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

Applied Therapeutics: Pushing Towards FDA Approval

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

Consensus revenue estimates decrease by 38%

Consensus revenue estimates decrease by 26%

Forecast to breakeven in 2026

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

Chair of the Board of Directors recently sold US$1.7m worth of stock

New major risk - Revenue and earnings growth

Applied Therapeutics, Inc. announced that it expects to receive $99.997998 million in funding from a group of investors

Applied Therapeutics, Inc. Announces Positive Interim 12-Month Results from the Ongoing Phase 3 Inspire Trial

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Applied Therapeutics, Inc. Announces Positive Results from 12-Month Interim Analysis of Govorestat (At-007) in the Ongoing Inspire Phase 3 Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Applied Therapeutics, Inc. Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

Independent Director recently bought US$65k worth of stock

Applied Therapeutics, Inc. Appoints Les Funtleyder as Chief Financial Officer, Effective November 20, 2023

Consensus EPS estimates fall by 36%

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

New major risk - Shareholder dilution

Consensus EPS estimates fall by 13%

Consensus revenue estimates fall by 27%

New major risk - Financial position

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Consensus revenue estimates decrease by 21%

Consensus revenue estimates increase by 89%

Consensus revenue estimates increase by 1,731%

Applied Therapeutics Announces Positive Sorbitol Reduction Data from the Ongoing Phase 3 Inspire Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Price target increased by 27% to US$15.00

Insufficient new directors

Price target increased to US$16.50

Applied Therapeutics, Inc.(NasdaqGM:APLT) dropped from Russell 2000 Growth Index

Applied Therapeutics Receives Orphan Medicinal Product Designation from the Ema for AT-007 for Treatment of Galactosemia

Insufficient new directors

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society

Price target decreased to US$12.10

Applied Therapeutics, Inc., Annual General Meeting, Jun 02, 2022